Tiberend Strategic Advisors, Inc.

More from Azitra Inc's Travis Whitfill on the DNA Today Podcast What led you to Co-Found Azitra? What need did you see? Check out the full episode here: https://lnkd.in/epGin9wR

#Mentalhealth disorders are a global health concern. Unfortunately, current treatments are not good enough. First-line #SSRIs provide adequate relief for just ~40% of patents. #depression #anxiety #PTSD Learn how Enveric Biosciences, Inc. is working to bring innovative #neuroplastogens to patients in need.  https://lnkd.in/erkWa-P2

We are excited to see Rod Cotton, Venture Partner at 2Flo Ventures, highlight new treatments for septic shock as an underserved market opportunity for pharmaceutical innovators in the latest Scrip Asks 2025 Therapeutic Area Advances column! Vivacelle Bio, Inc., a 2Flo Ventures portfolio company, is advancing its lead product, VBI-S, in a Phase 3 clinical trial for hypovolemic septic shock. The company is positioning its therapy as a potential near-to-market solution for a disease that claims more lives per year than cancer.   Read Rod’s comments as well as opinions from other pharmaceutical industry leaders in the full article, accessible here: https://lnkd.in/dSyX8Mmu #HealthEquity

Exciting News from DeFloria, Inc.! We are thrilled to announce that the U.S. Food and Drug Administration (FDA) has advanced our orally delivered, multi-cannabinoid botanical drug, AJA001, to a Phase II clinical trial to investigate its effects on irritability stemming from autism spectrum disorder (ASD) in children and adults. As Dr. Orrin Devinsky, our Chief Medical Advisor, stated, "DeFloria is at the forefront of advancing a promising drug for this indication through the FDA's rigorous assessment process to potentially help millions affected by autism spectrum disorder." Joel Stanley, AJNA BioSciences CEO and Chairman of the Board, reflected on the journey: "For more than 15 years, my family and our team have been laying the foundation for this botanical drug. Charlotte Figi's story, shared by Dr. Sanjay Gupta on CNN, put the benefits of cannabinoids on the world's radar and sparked a movement. Now, with this Phase 2 milestone, we're one step closer to delivering a potential treatment option for autism spectrum disorder, a condition for which few effective therapies exist despite impacting millions worldwide." Thank you to everyone who has supported us on this journey. Together, we strive toward a brighter future for those affected by autism spectrum disorder! https://lnkd.in/d2VnACJ5 #DeFloria #AjnaBioSciences #CharlottesWebCBD #Cannabinoids #FDA #ClinicalTrials #AutismAwareness

Check out Enveric Biosciences, Inc. CEO Joe Tucker from this year's #SACHS_NIF The 8th Annual Neuroscience Innovation Forum from last month - The Future of #Psychedelics Panel - Thanks to Sachs Associates #neurophallucinogenic #nonhallucinogenic

Cognition Therapeutics, Inc. CEO Lisa Ricciardi was interviewed at BIO CEO & Investor Conference and was featured in BioWorld News. Thank you to Managing Editor Karen Carey for taking time to speak with Lisa.

Lakewood-Amedex Inc. Announces Leadership Changes https://lnkd.in/esKe6sTj Doug Manion, Kelvin Cooper, Peter Ceccacci, Thomas Balzer

Thanks Eleanor Malone and Citeline for including Enveric Biosciences, Inc.’s CEO Joe Tucker in the its #ScripAsks: What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends. https://lnkd.in/eHgUfmpT

In case you missed our news this morning - Enveric Biosciences, Inc. and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease - https://lnkd.in/eR4jKn7d